Articles related to NARCOLEPSY
Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1
In a recent phase 2 trial involving patients with narcolepsy type 1, oral orexin receptor 2-selective agonist TAK-994 exhibited promising results in improving sleep latency and reducing cataplexy. However, the study was terminated early due to hepatotoxic effects, underscoring the need for further evaluation and refinement of the treatment approach.
Neurology August 2nd 2023
“Tentative Approval”: Understanding the FDA Ruling on Once-Nightly Sodium Oxybate
Approved? Not-approved? What is “tentative approval?” Clinical trial data on this novel “once nightly” sodium oxibate showed the drug to be acceptable for narcolepsy. But legal issues are holding up the FDA approval process.
Internal Medicine January 18th 2023
Update on Treatment Options for Narcolepsy
After completing this 3-chapter, 0.25-credit CME program, participants should be better able to assess the effectiveness and safety of current and novel therapies in improving outcomes for narcolepsy patients. They should also be able to define the methods by which patients and healthcare professionals can collaborate more effectively to define treatment goals and make decisions that will improve therapeutic outcomes.
Internal Medicine November 8th 2022